vTv Therapeutics Inc. Form SC 13D/A February 15, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 19)*

vTv Therapeutics Inc. (Name of Issuer)

Class A common stock, par value \$0.01 per share (Title of Class of Securities)

918385 105 (CUSIP Number)

Steven M. Cohen
Executive Vice President, Chief Administrative Officer and General Counsel
MacAndrews & Forbes Incorporated
35 East 62nd Street
New York, NY 10065
212-572-8600
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

With copies to: Lawrence G. Wee Paul, Weiss, Rifkind, Wharton & Garrison LLP 1285 Avenue of the Americas New York, NY 10019-6064 (212) 373-3000

February 14, 2019 (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-l(f) or 240.13d-l(g), check the following box.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Exchange Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.	SCHEDULE 13D Page 2 of 11
918385 105	SCHEDULE ISD Page 2 of 11

1	NAME OF REPORTING PERSON The ROP Revocable Trust dated 1/9/2018	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	(a)
3	SEC USE ONLY	(b)
4	SOURCE OF FUNDS (SEE INSTRUCTIONS) OO	
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)	
6	CITIZENSHIP OR PLACE OF ORGANIZATION New York	
NUMBER OF SHARES BENEFICIALY OWNED BY EACH REPORTING	SOLE VOTING POWER 0 SHARED VOTING POWER 41,994,072 (1)	
PERSON WITH	SOLE DISPOSITIVE POWER	

9 0 SHARED DISPOSITIVE POWER 10 41,994,072 (1)

41,994,072 (1)

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

85.5% (2)

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

13

12

00

The information set forth in Item 5 is incorporated by reference. The number of shares reported above includes (i) 15,678,436 shares of Class A common stock, par value \$0.01 per share (<u>"Class A Common Stock</u>"), of the Issuer, (ii) 23,084,267 shares of Class A Common Stock issuable upon exchange of 23,084,267 shares of Class B common stock, par value \$0.01 per share (<u>"Class B Common Stock</u>"), of the Issuer and corresponding nonvoting common units (<u>"vTv Units</u>") of vTv Therapeutics LLC, (iii) 1,057,455 shares of Class A Common Stock issuable to MacAndrews & Forbes Group LLC (<u>"M&F Group</u>") upon exercise of Common Stock issuable to M&F Group at the option of M&F Group pursuant to a commitment letter, dated December 11, 2018 (the <u>"Letter Agreement</u>") that are beneficially owned by the <u>"Reporting Persons</u>" (as defined below). The Reporting Person disclaims any beneficial ownership of the shares of Class A Common Stock and Class B Common Stock and corresponding vTv Units that may be deemed to be directly beneficially owned by the Ronald O. Perelman Trust.

The calculation assumes that there is a total of 49,118,306 shares of Class A Common Stock outstanding, which is the sum of (i) 22,792,716 shares of Class A Common Stock outstanding, (ii) 23,094,221 shares of Class A Common Stock that are issuable in exchange for the 23,094,221 shares of Class B Common Stock and (2) corresponding vTv Units outstanding, (iii) 1,057,455 shares of Class A Common Stock issuable to M&F Group upon exercise of the Warrants and (iv) 2,173,914 shares of Class A Common Stock issuable to M&F Group

pursuant to the Letter Agreement, in each case, as of February 14, 2019.

CUSIP No. 918385 105 SCH	EDU	LE 13D Page 3 of 11				
1	NAME OF REPORTING PERSON					
	MacAndrews & Forbes Incorporated					
2	AM	ECK THE APPROPRIATE BOX IF IEMBER OF A GROUP (SEE TRUCTIONS)	(a)			
			(b)			
3	SEC	C USE ONLY				
4 I		SOURCE OF FUNDS (SEE INSTRUCTIONS)				
		00				
5	PRO	ECK IF DISCLOSURE OF LEGAL OCEEDINGS IS REQUIRED RSUANT TO ITEMS 2(D) OR 2(E)				
6	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
	7	SOLE VOTING POWER				
NUMBER OF		0				
SHARES BENEFICIALY	8	SHARED VOTING POWER				
OWNED BY EACH REPORTING PERSON WITH	0	41,288,638 (1)				
	9	SOLE DISPOSITIVE POWER				
		0				
	10	SHARED DISPOSITIVE POWER				
	10	41,288,638 (1)				

41,288,638 (1)

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

84.1% (2)

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

13

12

CO

The information set forth in Item 5 is incorporated by reference. The number of shares reported above includes (i) 15,678,436 shares of Class A Common Stock, (ii) 22,378,833 shares of Class A Common Stock issuable upon exchange of 22,378,833 shares of Class B Common Stock and corresponding vTv Units, (iii) 1,057,455 shares of Class A Common Stock issuable to M&F Group upon exercise of the Warrants and (iv) 2,173,914 shares of Class A Common Stock issuable to M&F Group at the option of M&F Group pursuant to the Letter Agreement that are beneficially owned by the Reporting Persons. The Reporting Person disclaims any beneficial ownership of the shares of Class A Common Stock and Class B Common Stock, except to the extent of such Reporting Person's pecuniary interest therein.

The calculation assumes that there is a total of 49,118,306 shares of Class A Common Stock outstanding, which is the sum of (i) 22,792,716 shares of Class A Common Stock outstanding, (ii) 23,094,221 shares of Class A
(2) Common Stock that are issuable in exchange for the 23,094,221 shares of Class B Common Stock and corresponding vTv Units outstanding, (iii) 1,057,455 shares of Class A Common Stock issuable to M&F Group upon exercise of the Warrants and (iv) 2,173,914 shares of Class A Common Stock issuable to M&F Group pursuant to the Letter Agreement, in each case, as of February 14, 2019.

CUSIP No. 918385 105 SCH	EDU	LE 13D Page 4 of 11				
1	NAME OF REPORTING PERSON					
	MacAndrews & Forbes LLC					
2	AM	ECK THE APPROPRIATE BOX IF IEMBER OF A GROUP (SEE TRUCTIONS)	(a)			
			(b)			
3	SEC	C USE ONLY				
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)					
	00	00				
5	PRO	ECK IF DISCLOSURE OF LEGAL DCEEDINGS IS REQUIRED RSUANT TO ITEMS 2(D) OR 2(E)				
6	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
NUMBER OF SHARES BENEFICIALY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER				
	8	SHARED VOTING POWER 16,509,139 (1)				
	9	SOLE DISPOSITIVE POWER				
	10	SHARED DISPOSITIVE POWER 16,509,139 (1)				

16,509,139 (1)

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

TYPE OF REPORTING PERSON

(SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN 13 ROW (11)

33.6% (2)

14

12

00

The information set forth in Item 5 is incorporated by reference. The number of shares reported above includes (i) 13,277,770 shares of Class A Common Stock, (ii) 1,057,455 shares of Class A Common Stock issuable to M&F Group upon exercise of the Warrants and (iii) 2,173,914 shares of Class A Common Stock issuable to M&F Group at the option of M&F Group pursuant to the Letter Agreement.

The calculation assumes that there is a total of 49,118,306 shares of Class A Common Stock outstanding, which is the sum of (i) 22,792,716 shares of Class A Common Stock outstanding, (ii) 23,094,221 shares of Class A
 (2) Common Stock that are issuable in exchange for the 23,094,221 shares of Class B Common Stock and corresponding vTv Units outstanding, (iii) 1,057,455 shares of Class A Common Stock issuable to M&F Group upon exercise of the Warrants and (iv) 2,173,914 shares of Class A Common Stock issuable to M&F Group pursuant to the Letter Agreement, in each case, as of February 14, 2019.

CUSIP No. 918385 105 SCH	EDU	LE 13D Page 5 of 11				
1	NAME OF REPORTING PERSON					
	Mac	MacAndrews & Forbes Group LLC				
2	AM	ECK THE APPROPRIATE BOX IF IEMBER OF A GROUP (SEE TRUCTIONS)	(a)			
			(b)			
3	SEC	CUSE ONLY				
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)					
	00	00				
5	PRO	ECK IF DISCLOSURE OF LEGAL DCEEDINGS IS REQUIRED RSUANT TO ITEMS 2(D) OR 2(E)				
6		IZENSHIP OR PLACE OF GANIZATION				
	Delaware					
NUMBER OF SHARES BENEFICIALY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER				
	0	SHARED VOTING POWER				
	8	16,509,139 (1)				
	9	SOLE DISPOSITIVE POWER				
	10	SHARED DISPOSITIVE POWER 16,509,139 (1)				

16,509,139 (1)

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

TYPE OF REPORTING PERSON

(SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN 13 ROW (11)

33.6% (2)

14

12

00

The information set forth in Item 5 is incorporated by reference. The number of shares reported above includes (i) 13,277,770 shares of Class A Common Stock, (ii) 1,057,455 shares of Class A Common Stock issuable to M&F Group upon exercise of the Warrants and (iii) 2,173,914 shares of Class A Common Stock issuable to M&F Group at the option of M&F Group pursuant to the Letter Agreement.

The calculation assumes that there is a total of 49,118,306 shares of Class A Common Stock outstanding, which is the sum of (i) 22,792,716 shares of Class A Common Stock outstanding, (ii) 23,094,221 shares of Class A
 (2) Common Stock that are issuable in exchange for the 23,094,221 shares of Class B Common Stock and corresponding vTv Units outstanding, (iii) 1,057,455 shares of Class A Common Stock issuable to M&F Group upon exercise of the Warrants and (iv) 2,173,914 shares of Class A Common Stock issuable to M&F Group pursuant to the Letter Agreement, in each case, as of February 14, 2019.

CUSIP No. 918385 105 SCHEDULE 13D Page 6 of 11						
1	NAME OF REPORTING PERSON					
	MF	MFV Holdings One LLC				
2	AM	ECK THE APPROPRIATE BOX IF IEMBER OF A GROUP (SEE TRUCTIONS)	(a)			
			(b)			
3	SEC	C USE ONLY				
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)					
	00	00				
5	PRC	ECK IF DISCLOSURE OF LEGAL DCEEDINGS IS REQUIRED RSUANT TO ITEMS 2(D) OR 2(E)				
6	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
	7	SOLE VOTING POWER				
NUMBER OF	/	0				
SHARES BENEFICIALY	0	SHARED VOTING POWER				
OWNED BY EACH REPORTING PERSON WITH	8	24,779,499 (1)				
	9	SOLE DISPOSITIVE POWER				
		0				
	10	SHARED DISPOSITIVE POWER				
	10	24,779,499 (1)				

24,779,499 (1)

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN 13 ROW (11)

54.0% (2)

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

12

00

The information set forth in Item 5 is incorporated by reference. The number of shares reported above includes (1)22,378,833 shares of Class B Common Stock and corresponding vTv Units, which are exchangeable for 22,378,833 shares of Class A Common Stock.

The calculation assumes that there is a total of 45,886,937 shares of Class A Common Stock outstanding, which is (2) the sum of (i) 22,792,716 shares of Class A Common Stock outstanding and (ii) 23,094,221 shares of Class A Common Stock that are issuable in exchange for the 23,094,221 shares of Class B Common Stock and corresponding vTv Units outstanding, in each case, as of February 14, 2019.

CUSIP No. 918385 105 SCH	EDU	LE 13D Page 7 of 11				
1	NAME OF REPORTING PERSON					
	M&F TTP Holdings LLC					
2	A M	ECK THE APPROPRIATE BOX IF IEMBER OF A GROUP (SEE TRUCTIONS)	(a)			
			(b)			
3	SEC	CUSE ONLY				
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)					
	00	00				
5	PRO	ECK IF DISCLOSURE OF LEGAL OCEEDINGS IS REQUIRED RSUANT TO ITEMS 2(D) OR 2(E)				
6	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
NUMBER OF	7	SOLE VOTING POWER				
SHARES BENEFICIALY		SHARED VOTING POWER				
OWNED BY EACH REPORTING PERSON WITH	8	22,378,833 (1)				
	9	SOLE DISPOSITIVE POWER				
	10	SHARED DISPOSITIVE POWER 22,378,833 (1)				

22,378,833 (1)

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN 13 ROW (11)

48.8% (2)

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

12

00

The information set forth in Item 5 is incorporated by reference. The number of shares reported above represents (1)22,378,833 shares of Class B Common Stock and corresponding vTv Units, which are exchangeable for 22,378,833 shares of Class A Common Stock.

The calculation assumes that there is a total of 45,886,937 shares of Class A Common Stock outstanding, which is (2) the sum of (i) 22,792,716 shares of Class A Common Stock outstanding and (ii) 23,094,221 shares of Class A Common Stock that are issuable in exchange for the 23,094,221 shares of Class B Common Stock and corresponding vTv Units outstanding, in each case, as of February 14, 2019.

CUSIP No. 918385 105 SCH	EDU	LE 13D Page 8 of 11				
1	NAME OF REPORTING PERSON					
	M&F TTP Holdings Two LLC					
2	AM	ECK THE APPROPRIATE BOX IF IEMBER OF A GROUP (SEE TRUCTIONS)	(a)			
			(b)			
3	SEC	CUSE ONLY				
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)					
	00	00				
5	PRO	ECK IF DISCLOSURE OF LEGAL OCEEDINGS IS REQUIRED RSUANT TO ITEMS 2(D) OR 2(E)				
6	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Dela	aware				
NUMBER OF	7	SOLE VOTING POWER				
SHARES BENEFICIALY	0	SHARED VOTING POWER				
OWNED BY EACH REPORTING PERSON WITH	8	22,378,833 (1)				
	9	SOLE DISPOSITIVE POWER				
	10	SHARED DISPOSITIVE POWER 22,378,833 (1)				

22,378,833 (1)

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN 13 ROW (11)

48.8% (2)

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

12

00

The information set forth in Item 5 is incorporated by reference. The number of shares reported above represents (1)22,378,833 shares of Class B Common Stock and corresponding vTv Units, which are exchangeable for 22,378,833 shares of Class A Common Stock.

The calculation assumes that there is a total of 45,886,937 shares of Class A Common Stock outstanding, which is (2) the sum of (i) 22,792,716 shares of Class A Common Stock outstanding and (ii) 23,094,221 shares of Class A Common Stock that are issuable in exchange for the 23,094,221 shares of Class B Common Stock and corresponding vTv Units outstanding, in each case, as of February 14, 2019.

8

Edgar Filing: vTv Therapeutics Inc. - Form SC 13D/A

CUSIP No. 918385 105 SCHEDULE 13D Page 9 of 11

This Amendment No. 19 ("Amendment No. 19") amends and supplements the statement on Schedule 13D, dated August 14, 2015, as amended by Amendment No. 1 to the statement on Schedule 13D, dated August 28, 2015, as further amended by Amendment No. 2 to the statement on Schedule 13D, dated October 5, 2015, as further amended by Amendment No. 3 to the statement on Schedule 13D, dated April 6, 2016, as further amended by Amendment No. 4 to the statement on Schedule 13D, dated August 15, 2017, as further amended by Amendment No. 5 to the statement on Schedule 13D, dated December 7, 2017, as further amended by Amendment No. 6 to the statement on Schedule 13D, dated May 29, 2018, as further amended by Amendment No. 7 to the statement on Schedule 13D, dated June 20, 2018, as further amended by Amendment No. 8 to the statement on Schedule 13D, dated July 10, 2018, as further amended by Amendment No. 9 to the statement on Schedule 13D, dated August 1, 2018, as further amended by Amendment No. 10 to the statement on Schedule 13D, dated August 14, 2018, as further amended by Amendment No. 11 to the statement on Schedule 13D, dated September 10, 2018, as further amended by Amendment No. 12 to the statement on Schedule 13D, dated October 1, 2018, as further amended by Amendment No. 13 to the statement on Schedule 13D, dated November 6, 2018, as further amended by Amendment No. 14 to the statement on Schedule 13D, dated November 29, 2018, as further amended by Amendment No. 15 to the statement on Schedule 13D, dated December 12, 2018, as further amended by Amendment No. 16 to the statement on Schedule 13D, dated December 27, 2018, as further amended by Amendment No. 17 to the statement on Schedule 13D, dated January 18, 2019, and as further amended by Amendment No. 18 to the statement on Schedule 13D, dated January 30, 2019 (as so amended, the "Schedule 13D"), and is being filed with the Securities and Exchange Commission by The ROP Revocable Trust dated 1/9/2018, a New York trust, MacAndrews & Forbes Incorporated, a Delaware corporation ("MacAndrews & Forbes"), MacAndrews & Forbes LLC, a Delaware limited liability company ("M&F LLC"), MacAndrews & Forbes Group LLC, a Delaware limited liability company ("M&F Group"), MFV Holdings One LLC, a Delaware limited liability company ("MFV"), M&F TTP Holdings LLC, a Delaware limited liability company ("M&F TTP"), and M&F TTP Holdings Two LLC, a Delaware limited liability company ("M&F TTP Two") (each of the foregoing, a "Reporting Person," and collectively, the "Reporting Persons"), relating to the shares of the Class A common stock, par value \$0.01 per share ("Class A Common Stock"), of vTv Therapeutics Inc., a Delaware corporation (the "Issuer").

Item 3. Source and Amount of Funds or Other Consideration.

The information contained in Item 3 of the Schedule 13D is hereby amended and supplemented by adding the information below.

On February 14, 2019, M&F Group purchased 815,217 shares of Class A Common Stock from the Issuer pursuant to the terms of the previously disclosed letter agreement, dated as of December 11, 2018, between M&F Group and the Issuer. The funds used for the purchase of 815,217 shares of the Class A Common Stock were derived from general working capital. A total of \$1,500,000 in cash was paid to acquire such shares.

Item 5. Interest in Securities of the Issuer

The information contained in the first four paragraphs of Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a) The ROP Revocable Trust directly or indirectly controls MacAndrews & Forbes, M&F LLC, M&F Group, MFV, M&F TTP and M&F TTP Two. Including (i) the 23,084,267 shares of Class B Common Stock (which are exchangeable, together with a corresponding vTv Unit, for shares of Class A Common Stock on a one-to-one basis) outstanding, (ii) 1,057,455 shares of Class A Common Stock issuable to M&F Group upon exercise of the Warrants and (iii) 2,173,914 shares of Class A Common Stock issuable to M&F Group pursuant to the Letter Agreement:

·41,994,072 shares of Class A Common Stock are beneficially owned by Mr. Perelman and the ROP Revocable Trust;

Edgar Filing: vTv Therapeutics Inc. - Form SC 13D/A

·41,288,638 shares of Class A Common Stock are beneficially owned by MacAndrews & Forbes;

·24,779,499 shares of Class A Common Stock are beneficially owned by MFV;

·22,378,833 shares of Class A Common Stock are beneficially owned by M&F TTP and M&F TTP Two; and

·16,509,139 shares of Class A Common Stock are beneficially owned by M&F LLC and M&F Group.

Each of the Reporting Persons disclaim any beneficial ownership of the shares of Class A Common Stock and Class B Common Stock, except to the extent of such Reporting Person's pecuniary interest therein.

9

CUSIP No. 918385 105 SCHEDULE 13D Page 10 of 11

Ronald O. Perelman, the sole trustee and sole beneficiary of the ROP Revocable Trust and the Director, Chairman and Chief Executive Officer of MacAndrews & Forbes, may be deemed to beneficially own all the shares of Class A Common Stock and Class B Common Stock beneficially owned by the ROP Revocable Trust, MacAndrews & Forbes, M&F LLC, M&F Group, MFV, M&F TTP and M&F TTP Two. The number of shares reported as beneficially owned by the ROP Revocable Trust includes 49,713 shares of Class B Common Stock and corresponding vTv Units that may be deemed to be directly beneficially owned by the Ronald O. Perelman Trust. Mr. Perelman disclaims any beneficial ownership of the shares of Class A Common Stock and Class B Common Stock, except to the extent of their pecuniary interest therein.

The total Class A Common Stock beneficial ownership of (i) Mr. Perelman and the ROP Revocable Trust represents approximately 85.5% of the Class A Common Stock, (ii) MacAndrews & Forbes represents approximately 84.1% of the Class A Common Stock, (iii) MFV represents approximately 54.0% of the Class A Common Stock, (iv) M&F TTP and M&F TTP Two represents approximately 48.8% of the Class A Common Stock and (v) M&F LLC and M&F Group represents approximately 33.6% of the Class A Common Stock (assuming, in the case of MFV, M&F TTP and M&F TTP Two, that there is a total of 45,886,937 shares of Class A Common Stock outstanding, which is the sum of (i) 22,792,716 shares of Class A Common Stock outstanding and (ii) 23,094,221 shares of Class A Common Stock that are issuable in exchange for the 23,094,221 shares of Class B Common Stock and corresponding vTv Units outstanding, in each case, as of February 14, 2019, and, in the case of the beneficial ownership of Mr. Perelman, the ROP Revocable Trust, MacAndrews & Forbes, M&F LLC and M&F Group, that there is a total of 49,118,306 shares of Class A Common Stock outstanding, which is the sum of (i) 22,792,716 shares of Class A Common Stock outstanding, (ii) 23,094,221 shares of Class A Common Stock outstanding, (iii) 1,057,455 shares of Class A Common Stock issuable to M&F Group upon exercise of the Warrants and (iv) 2,173,914 shares of Class A Common Stock issuable to M&F Group pursuant to the Letter Agreement, in each case, as of February 14, 2019).

The responses of each Reporting Person to Items 7 through 11 of the cover pages of this Schedule 13D relating to beneficial ownership of the shares of Class A Common Stock are incorporated herein by reference.

(c) Except for the transactions described herein, there have been no other transactions in the securities of the Issuer effected by the Reporting Persons since the filing of Amendment No. 18 to this Schedule 13D.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The information contained in Item 6 of the Schedule 13D is hereby amended and supplemented by adding the information below.

Joint Filing Agreement

Pursuant to Rule 13d-1(k) promulgated under the Exchange Act, the Reporting Persons have entered into an agreement on February 15, 2019 with respect to the joint filing of this Schedule 13D and any amendment or amendments thereto (the <u>"Joint Filing Agreement</u>"). The Joint Filing Agreement is attached hereto as Exhibit 1 and incorporated herein by reference.

Item 7. Material to be Filed as Exhibits

Exhibit Joint Filing Agreement, dated February 15, 2019, between the ROP Revocable Trust, MacAndrews & Forbes 1: Incorporated, MacAndrews & Forbes LLC, MacAndrews & Forbes Group LLC, MFV Holdings One LLC,

M&F TTP Holdings LLC and M&F TTP Holdings Two LLC.

10

CUSIP No. 918385 105 SCHEDULE 13D Page 11 of 11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 15, 2019

The ROP Revocable Trust dated 1/9/2018

By:/s/ Ronald O. Perelman Name:Ronald O. Perelman Title: Trustee

MacAndrews & Forbes Incorporated

- By: /s/ Shiri Ben-Yishai Name: Shiri Ben-Yishai Title: Senior Vice President and Secretary
- MacAndrews & Forbes LLC
- By: /s/ Shiri Ben-Yishai Name: Shiri Ben-Yishai Title: Senior Vice President and Secretary

MacAndrews & Forbes Group LLC

By: /s/ Shiri Ben-Yishai Name: Shiri Ben-Yishai Title: Senior Vice President and Secretary

MFV Holdings One LLC

By: /s/ Shiri Ben-Yishai Name: Shiri Ben-Yishai Title: Senior Vice President and Secretary

M&F TTP Holdings LLC

By: /s/ Shiri Ben-Yishai Name: Shiri Ben-Yishai Title: Senior Vice President and Secretary

M&F TTP Holdings Two LLC

By: /s/ Shiri Ben-Yishai Name: Shiri Ben-Yishai Title: Senior Vice President and Secretary